Table 1.
Clinicopathological characteristics and paclitaxel responses of NSCLC patients with and without P16 methylation from the clinical trial
| N | P16 Methylation | P- value | ||
|---|---|---|---|---|
| Negative cases (%) | Positive cases (%) | |||
| (All) | 45* | 30 (66.7) | 15 (33.3) | |
| Gender | 1.000 | |||
| Male | 38 | 25 (65.8) | 13 (34.2) | |
| Female | 7 | 5 (71.4) | 2 (28.6) | |
| Age | 0.019 | |||
| <60y | 26 | 21 (80.8) | 5 (19.2) | |
| ≥60y | 19 | 9 (47.4) | 10 (52.6) | |
| Pathology type | ||||
| Squamous carcinoma | 26 | 14 (53.8) | 12 (46.2) | 0.031 |
| Adenocarcinoma | 17 | 14 (82.4) | 3 (17.6) | |
| Large cell carcinoma | 2 | 2 (100) | 0 | |
| Clinical stage | 0.454 | |||
| IIIA | 9 | 5 (55.6) | 4 (44.4) | |
| IIIB | 36 | 25 (69.4) | 11 (30.6) | |
| Therapy response | 0.004 | |||
| Total response | 18 | 16 (53.3) | 2 (13.3) | |
| Complete response | 1 | 0 | 1 | |
| Partial response | 17 | 16 (94.1) | 1 (5.9) | |
| No response | 27 | 14 (46.7) | 13 (86.7) | |
| Stable | 18 | 9 (50.0) | 9 (50.0) | |
| Progression | 9 | 5 (55.6) | 4 (54.4) | |
* 23 cases from Arm-1 and 22 cases from Arm-2 in the clinical trial